Pfizer Loses Lyrica Patent Battle in UK Supreme Court

Drug Industry Daily
A A
Pfizer’s appeal for a second patent on Lyrica (pregabalin) has been denied by the UK’s highest court, ending the pharma giant’s long-running fight against drug companies marketing generic versions of its blockbuster pain treatment.

To View This Article:

Login

Subscribe To Drug Industry Daily